BioCentury | Sep 16, 2020
Management Tracks

HHS follows FDA, replacing political communications leader with career staff

...also announced the departure of Paul Alexander, a part-time assistant professor of health research at McMaster University...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...President and CEO Paul Lammers told BioCentury.Launched in 2015 based on scientific work out of McMaster University...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...Brain cancer CAR T therapy A McMaster University and University of Toronto team revealed in a Cell...
...Kopke, Staff Writer and Karen Tkach Tuzman, Associate Editor CX-5461 American Society of Clinical Oncology ASCO Weizmann Institute of Science McMaster University Empirica...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Two glycopeptides for drug-resistant Gram-positive infections

...published online Feb. 12, 2020 doi:10.1038/s41586-020-1990-9 CONTACT: Gerard D. Wright, McMaster University, Hamilton, Ontario email: wrightge@mcmaster.ca Claire Quang McMaster University...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

...Eric Brown, respectively. Barzilay is a professor at MIT, and Brown is a professor at McMaster University...
...properties," he said. Targets JNK - c-jun N-terminal kinase Karen Tkach Tuzman, Associate Editor Massachusetts Institute of Technology McMaster University c-jun...
BioCentury | Apr 19, 2019
Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...MSI1 stands out, with two groups presenting strategies to therapeutically target its activity. Researchers from McMaster University...
...Wilmington, Del. Johns Hopkins University, Baltimore, Md. Kanazawa University, Kanazawa, Japan McGill University, Montreal, Quebec McMaster University...
BioCentury | Mar 8, 2019
Clinical News

Higher dose of tanezumab meets in latest Phase III pain readout

Pfizer and partner Eli Lilly reported on Feb. 19 that the 10 mg dose of tanezumab met the primary endpoint in the Phase III A4091059 trial to treat chronic low back pain. The data follow...
BioCentury | Feb 8, 2019
Company News

Mannin, McMaster partner to develop MAN-01

...Mannin Research Inc. (Toronto, Ontario) partnered with McMaster University (Ontario, Canada) to develop Mannin's MAN-01, a small...
...end of 4Q19. Mannin Research Inc., Toronto, Ontario McMaster University, Ontario, Canada Business: Ophthalmic Shannon Lehnbeuter MAN-01 Mannin Research Inc. McMaster University...
Items per page:
1 - 10 of 217
BioCentury | Sep 16, 2020
Management Tracks

HHS follows FDA, replacing political communications leader with career staff

...also announced the departure of Paul Alexander, a part-time assistant professor of health research at McMaster University...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...President and CEO Paul Lammers told BioCentury.Launched in 2015 based on scientific work out of McMaster University...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...Brain cancer CAR T therapy A McMaster University and University of Toronto team revealed in a Cell...
...Kopke, Staff Writer and Karen Tkach Tuzman, Associate Editor CX-5461 American Society of Clinical Oncology ASCO Weizmann Institute of Science McMaster University Empirica...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Two glycopeptides for drug-resistant Gram-positive infections

...published online Feb. 12, 2020 doi:10.1038/s41586-020-1990-9 CONTACT: Gerard D. Wright, McMaster University, Hamilton, Ontario email: wrightge@mcmaster.ca Claire Quang McMaster University...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

...Eric Brown, respectively. Barzilay is a professor at MIT, and Brown is a professor at McMaster University...
...properties," he said. Targets JNK - c-jun N-terminal kinase Karen Tkach Tuzman, Associate Editor Massachusetts Institute of Technology McMaster University c-jun...
BioCentury | Apr 19, 2019
Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...MSI1 stands out, with two groups presenting strategies to therapeutically target its activity. Researchers from McMaster University...
...Wilmington, Del. Johns Hopkins University, Baltimore, Md. Kanazawa University, Kanazawa, Japan McGill University, Montreal, Quebec McMaster University...
BioCentury | Mar 8, 2019
Clinical News

Higher dose of tanezumab meets in latest Phase III pain readout

Pfizer and partner Eli Lilly reported on Feb. 19 that the 10 mg dose of tanezumab met the primary endpoint in the Phase III A4091059 trial to treat chronic low back pain. The data follow...
BioCentury | Feb 8, 2019
Company News

Mannin, McMaster partner to develop MAN-01

...Mannin Research Inc. (Toronto, Ontario) partnered with McMaster University (Ontario, Canada) to develop Mannin's MAN-01, a small...
...end of 4Q19. Mannin Research Inc., Toronto, Ontario McMaster University, Ontario, Canada Business: Ophthalmic Shannon Lehnbeuter MAN-01 Mannin Research Inc. McMaster University...
Items per page:
1 - 10 of 217